Axiogenesis offers a range of in vitro assays to assess potential toxicity of chemicals, pharmaceutical compounds, or consumer goods. All assays are performed in a GLP-like set-up, and include generation of the study protocol, test article preparation, execution of the study, data analysis, and a full study report.
The following assays are available upon request:
- Structural Cardiotoxicity – Neutral Red Uptake or Troponin Release Assay using Axiogenesis’ human or mouse cardiomyocytes
- E-Screen – Detection of estrogeneic activity using the MCF-7 cell line
- General Cytotoxicity Screening – Detection of cytotoxicity of chemicals, pharmaceutical, or test material extracts (prepared according DIN ISO 10993-12 and DIN EN 1186-1); several read-outs possible and cell types possible (incl. stem cells)
Advantages ToxEffect Screening
- Comprehensive collection of proven in vitro assays to cover the most severe toxicity endpoints.
- Predictive, relevant and robust cell culture test battery capable of medium throughput screening.
- Detection of the biological effect of a hazardous component is possible even if the toxic agent itself is unknown.
- Testing of consumer goods possible due to robust and relevant extraction technique (according to DIN ISO 10993-12 and DIN EN 1186·1).
- Early and quick results makes ToxEffect Screening suitable for supply chain verification.